Αποτελέσματα Αναζήτησης
Dianthus Therapeutics is leading the next generation of complement antibody therapeutics with best-in-class potential to address high unmet medical needs for patients.
- Careers
Dianthus Therapeutics is aware of a surge in email scams...
- Approach & Pipeline
Dianthus Therapeutics (Dianthus) respects the privacy of...
- INVESTORS & NEWS
To Harness the Power of Selectivity in Complement...
- Careers
Magenta Therapeutics is a clinical-stage biotech company developing medicines for stem cell transplants. Learn about its mission, products, employees, and locations on LinkedIn.
11 Σεπ 2023 · Magenta Therapeutics Announces Completion of Merger with Dianthus Therapeutics and Implementation of Reverse Stock Split. The combined company will operate as “Dianthus Therapeutics, Inc.”...
3 Μαΐ 2023 · Magenta Therapeutics, Inc. will be renamed “Dianthus Therapeutics, Inc.” and the corporate headquarters will be co-located in New York, NY and Waltham, MA.
3 Μαΐ 2023 · Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement. Wed, May 3, 2023, 7:00 AM14 min read. Merger to create Nasdaq-listed, clinical-stage biotechnology company focused on...
12 Μαΐ 2021 · Magenta Therapeutics announced positive preliminary results of MGTA-145, a novel mobilization agent, in combination with plerixafor for stem cell transplant in multiple myeloma patients. The company also provided an update on its planned clinical trial of MGTA-117, a novel lymphodepletion agent, in AML and MDS patients.
12 Δεκ 2022 · Magenta Therapeutics is a biotech company developing novel medicines for stem cell transplant. It presents positive data from MGTA-117, a targeted conditioning product candidate for AML and MDS, and provides updates on CD45-ADC and MGTA-145.
